AIM Vaccine Co., Ltd.

SHSC:6660 Stock Report

Market Cap: HK$7.4b

AIM Vaccine Management

Management criteria checks 3/4

AIM Vaccine's CEO is Yan Zhou, appointed in Sep 2020, has a tenure of 4.25 years. total yearly compensation is CN¥2.18M, comprised of 86.5% salary and 13.5% bonuses, including company stock and options. directly owns 16.62% of the company’s shares, worth HK$1.22B. The average tenure of the management team and the board of directors is 3.6 years and 4.4 years respectively.

Key information

Yan Zhou

Chief executive officer

CN¥2.2m

Total compensation

CEO salary percentage86.5%
CEO tenure4.3yrs
CEO ownership16.6%
Management average tenure3.6yrs
Board average tenure4.4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Yan Zhou's remuneration changed compared to AIM Vaccine's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-CN¥1b

Mar 31 2024n/an/a

-CN¥1b

Dec 31 2023CN¥2mCN¥2m

-CN¥1b

Sep 30 2023n/an/a

-CN¥913m

Jun 30 2023n/an/a

-CN¥525m

Mar 31 2023n/an/a

-CN¥422m

Dec 31 2022CN¥2mCN¥2m

-CN¥320m

Dec 31 2021CN¥899mCN¥1m

-CN¥693m

Compensation vs Market: Yan's total compensation ($USD297.98K) is below average for companies of similar size in the Hong Kong market ($USD478.93K).

Compensation vs Earnings: Yan's compensation has increased whilst the company is unprofitable.

CEO

Yan Zhou (57 yo)

4.3yrs

Tenure

CN¥2,175,000

Compensation

Mr. Yan Zhou is Executive Chairman and Chief Executive Officer of AIM Vaccine Co., Ltd. September 2020. He has served as a Director of AIM Vaccine Co., Ltd.since May 2015 and was re-designated as an execu...

Leadership Team

NamePositionTenureCompensationOwnership
Yan Zhou
Executive Chairman & CEO4.3yrsCN¥2.18m16.62%
HK$ 1.2b
Xin Zhou
Executive Vice-Chairman & Executive President11.6yrsno data3.3%
HK$ 242.8m
Wen Guan
Vice-Chairman of the Board & Executive President3.8yrsCN¥2.23mno data
Jie Zhou
Executive Director & Executive Presidentless than a yearno data3.3%
HK$ 242.8m
Shaojun Jia
COO, Executive President & Executive Director3.8yrsCN¥2.43m0.84%
HK$ 61.7m
Lixin Niu
Chief Financial Officer9.2yrsno datano data
Ling Liu
Secretary & Chief Investment Officer9.1yrsno datano data
Zhang Fan
Chief Research Officer3.8yrsno datano data
Meng Li
Chief Quality Officer2.7yrsno datano data
Zhou Wenjuan
Chief Public Affairs Officer2.8yrsno datano data
Lin Zhenyu
Chief Marketing Officer2.8yrsno datano data
Wing Chi Lam
Joint Company Secretary3.5yrsno datano data

3.6yrs

Average Tenure

54yo

Average Age

Experienced Management: 6660's management team is considered experienced (3.6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Yan Zhou
Executive Chairman & CEO9.6yrsCN¥2.18m16.62%
HK$ 1.2b
Xin Zhou
Executive Vice-Chairman & Executive President11.6yrsno data3.3%
HK$ 242.8m
Wen Guan
Vice-Chairman of the Board & Executive President3.8yrsCN¥2.23mno data
Jie Zhou
Executive Director & Executive President9.6yrsno data3.3%
HK$ 242.8m
Shaojun Jia
COO, Executive President & Executive Director7.3yrsCN¥2.43m0.84%
HK$ 61.7m
Ker Wei Pei
Independent Non-Executive Director4.3yrsCN¥300.00kno data
Tingfeng Song
Chairman of The Supervisory Committee3.8yrsno datano data
Hui Ouyang
Independent Non-Executive Director3.6yrsCN¥300.00kno data
Aijun Wang
Non-Executive Director7.3yrsno data4.13%
HK$ 303.5m
Xiaoguang Guo
Independent Non-Executive Director3.8yrsCN¥300.00kno data
Jichen Zhao
Non-Executive Director4.5yrsno datano data
Jie Wen
Independent Non-Executive Director3.6yrsCN¥300.00kno data

4.4yrs

Average Tenure

58yo

Average Age

Experienced Board: 6660's board of directors are considered experienced (4.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 20:00
End of Day Share Price 2024/12/27 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

AIM Vaccine Co., Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tony RenMacquarie Research